FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280491761> ?p ?o ?g. }

• W4280491761 abstract "Dear Editor, We have studied humoral and cellular responses in a Spanish cohort of 433 volunteers immunized with four COVID-19 vaccines (Ad26.CoV2.S, BNT162b2, ChAdOx1 and mRNA-1273) approved by the European Medicines Agency (EMA), classified as naïve or recovered according to whether they were previously infected by SARS-CoV-2. Both humoral and cellular responses were higher in those naïve individuals immunized with mRNA-type vaccines (mRNA-1273 and BNT162b2) compared to those inoculated with viral-vector vaccines (ChAdOx1 and Ad26.CoV2.S). These differential responses over time were significantly attenuated in COVID-19-recovered subjects, as in these conditions we did not find any differences between the four vaccination regimens, neither with one nor two doses of ChAdOx1 or BNT162b2 vaccines in these individuals. We have recently reported that previous medical history of COVID-19 differentially determines the functional B and T cell-mediated responses to BNT162b2 vaccination over time.1 Herein, we have extended that study in a cohort of volunteers vaccinated with four regimens used in Spain. The volunteers were classified as either naïve or recovered according to whether they had been previously infected by the SARS-CoV-2 (Figure 1 and Supporting information Tables S1 and S2). Both BNT162b2 and mRNA-1273 induced higher levels of anti-Spike RBD IgG antibodies than viral-vector vaccines ChAdOx1 and Ad26.CoV2.S, remaining higher at least until 150 days after vaccination (Figure 2A). In addition, mRNA-based vaccines induced higher titers of neutralizing antibodies than viral-vector vaccines, keeping for around 90–150 days (Figure 2B) after which, such differences were not observed. Additionally, mRNA-based vaccines reached higher levels of anti-Spike RBD IgA antibodies than viral-vector vaccines only in the first 3 months post-vaccination (<90 days) perceiving low levels 90–210 days post-vaccination and without differences between all vaccination regimens (Supporting information Figure S1). Curiously, reduced levels of anti-Spike RBD IgA at late points (>150 days after full vaccination) coincide with the neutralization capacity downregulation (Figures 2B and Supporting information Figure S1). Other authors have reported that in natural infection anti-Spike RBD IgA antibodies showed to be the major responsible of the neutralizing ability in early stages.2 Regarding the cellular response, CD4+ but not CD8+ T-cell activities against SARS-CoV-2 spike peptide pool (Supporting information Figure S2A) remained high at late-time points in naïve individuals immunized with the mRNA-type vaccines (Figures 2C and Supporting information Figure S2B). SARS-CoV-2 spike-specific cytokines production also showed enhanced responses after vaccination with mRNA-type vaccines (Supporting information Figure S3). Additionally, these antigen-specific T-cell responses were characterized by a high proportion of effector and central memory subpopulations, but with a light decrease in effector memory T cells and an increase in central memory T cells long after vaccination (Supporting information Figure S4). Differential responses observed in naïve individuals over time were attenuated in COVID-19-recovered subjects. We did not find patent differences in the immune responses between the four vaccination regimens in recovered individuals, neither one nor two doses of BNT162b2 or ChAdOx1 vaccines (Figure 3). Besides, when comparing humoral and cellular responses between naïve and COVID-19-recovered subjects, we found higher anti-spike RBD IgG and neutralizing antibodies levels in recovered individuals, but no differences in the cellular CD4+ T-cell response were found (Figure 4). On 27 December 2020, the vaccination campaign began in Spain. One year later, this country had become one of the countries with the highest vaccination ranks, reaching a percentage of 80 of the population with a complete schedule. To date, the EMA has authorised five vaccines: ChAdOx1, Ad26.CoV2.S, mRNA-1273, BNT162b2 and NVX-CoV2373; however, the latter has not been administered in Spain. An extensive information on the prevention of hospitalization and mortality due to vaccination has been already assessed. Several studies performed in Spain confirm the impact of ratcheting up SARS-CoV-2 vaccination has had on declining COVID-19 hospitalizations and lethality rates, even though a lack of efficiency reducing the transmission rate was observed.3, 4 Additionally, these high ranks of vaccination have supposed a reduction in the use of medical resources with a high social returns.5 Nevertheless, a comparison between the differential immune responses triggered by each vaccine is still lacking. This is especially grievous in the case of cellular responses, since most studies solely focus on the antibody production.6 Additionally, a medical history of COVID-19 infection has usually been an exclusion criterion in most of the reported studies. Our findings support the use of mRNA-type vaccines for the induction of more robust humoral and cellular immune responses compared to viral-vector vaccines. Epidemiological data indicate BNT162b2 and mRNA-1273 vaccines have higher efficacy protecting against novel variants than the viral-vector ChAdOx1 and Ad26.CoV2.S vaccines.7, 8 Additionally, previous history SARS-CoV-2, seem to have even higher efficacy.9, 10 Our findings on immune responses provide new evidence for explaining these data. A booster dose, especially in naïve individuals vaccinated with Ad26.CoV2.S or ChAdOx1, would be recommended in order to reach levels of both humoral and cellular responses similar to those observed in COVID-19-recovered subjects. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W4280491761 created "2022-05-22" @default.
• W4280491761 creator A5000622587 @default.
• W4280491761 creator A5001313722 @default.
• W4280491761 creator A5001473189 @default.
• W4280491761 creator A5003491099 @default.
• W4280491761 creator A5004185547 @default.
• W4280491761 creator A5005608288 @default.
• W4280491761 creator A5006637145 @default.
• W4280491761 creator A5011309522 @default.
• W4280491761 creator A5019153950 @default.
• W4280491761 creator A5020948232 @default.
• W4280491761 creator A5025633739 @default.
• W4280491761 creator A5034663320 @default.
• W4280491761 creator A5036221680 @default.
• W4280491761 creator A5038576534 @default.
• W4280491761 creator A5040483533 @default.
• W4280491761 creator A5044919115 @default.
• W4280491761 creator A5047250028 @default.
• W4280491761 creator A5047255698 @default.
• W4280491761 creator A5050360251 @default.
• W4280491761 creator A5051538398 @default.
• W4280491761 creator A5051818344 @default.
• W4280491761 creator A5052225992 @default.
• W4280491761 creator A5062379217 @default.
• W4280491761 creator A5068694022 @default.
• W4280491761 date "2022-05-01" @default.
• W4280491761 modified "2023-10-05" @default.
• W4280491761 title "Prior SARS‐CoV‐2 infection balances immune responses triggered by four EMA‐approved COVID‐19 vaccines: An observational study" @default.
• W4280491761 cites W3112389805 @default.
• W4280491761 cites W3176668337 @default.
• W4280491761 cites W3199611357 @default.
• W4280491761 cites W3206462669 @default.
• W4280491761 cites W4200430875 @default.
• W4280491761 cites W4210814999 @default.
• W4280491761 cites W4212835565 @default.
• W4280491761 cites W4221037070 @default.
• W4280491761 cites W4226229183 @default.
• W4280491761 cites W4226443227 @default.
• W4280491761 doi "https://doi.org/10.1002/ctm2.869" @default.
• W4280491761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35538923" @default.
• W4280491761 hasPublicationYear "2022" @default.
• W4280491761 type Work @default.
• W4280491761 citedByCount "2" @default.
• W4280491761 countsByYear W42804917612023 @default.
• W4280491761 crossrefType "journal-article" @default.
• W4280491761 hasAuthorship W4280491761A5000622587 @default.
• W4280491761 hasAuthorship W4280491761A5001313722 @default.
• W4280491761 hasAuthorship W4280491761A5001473189 @default.
• W4280491761 hasAuthorship W4280491761A5003491099 @default.
• W4280491761 hasAuthorship W4280491761A5004185547 @default.
• W4280491761 hasAuthorship W4280491761A5005608288 @default.
• W4280491761 hasAuthorship W4280491761A5006637145 @default.
• W4280491761 hasAuthorship W4280491761A5011309522 @default.
• W4280491761 hasAuthorship W4280491761A5019153950 @default.
• W4280491761 hasAuthorship W4280491761A5020948232 @default.
• W4280491761 hasAuthorship W4280491761A5025633739 @default.
• W4280491761 hasAuthorship W4280491761A5034663320 @default.
• W4280491761 hasAuthorship W4280491761A5036221680 @default.
• W4280491761 hasAuthorship W4280491761A5038576534 @default.
• W4280491761 hasAuthorship W4280491761A5040483533 @default.
• W4280491761 hasAuthorship W4280491761A5044919115 @default.
• W4280491761 hasAuthorship W4280491761A5047250028 @default.
• W4280491761 hasAuthorship W4280491761A5047255698 @default.
• W4280491761 hasAuthorship W4280491761A5050360251 @default.
• W4280491761 hasAuthorship W4280491761A5051538398 @default.
• W4280491761 hasAuthorship W4280491761A5051818344 @default.
• W4280491761 hasAuthorship W4280491761A5052225992 @default.
• W4280491761 hasAuthorship W4280491761A5062379217 @default.
• W4280491761 hasAuthorship W4280491761A5068694022 @default.
• W4280491761 hasBestOaLocation W42804917611 @default.
• W4280491761 hasConcept C126322002 @default.
• W4280491761 hasConcept C159047783 @default.
• W4280491761 hasConcept C159654299 @default.
• W4280491761 hasConcept C203014093 @default.
• W4280491761 hasConcept C22070199 @default.
• W4280491761 hasConcept C2779134260 @default.
• W4280491761 hasConcept C3007834351 @default.
• W4280491761 hasConcept C3008058167 @default.
• W4280491761 hasConcept C32611913 @default.
• W4280491761 hasConcept C524204448 @default.
• W4280491761 hasConcept C71924100 @default.
• W4280491761 hasConcept C72563966 @default.
• W4280491761 hasConcept C8891405 @default.
• W4280491761 hasConceptScore W4280491761C126322002 @default.
• W4280491761 hasConceptScore W4280491761C159047783 @default.
• W4280491761 hasConceptScore W4280491761C159654299 @default.
• W4280491761 hasConceptScore W4280491761C203014093 @default.
• W4280491761 hasConceptScore W4280491761C22070199 @default.
• W4280491761 hasConceptScore W4280491761C2779134260 @default.
• W4280491761 hasConceptScore W4280491761C3007834351 @default.
• W4280491761 hasConceptScore W4280491761C3008058167 @default.
• W4280491761 hasConceptScore W4280491761C32611913 @default.
• W4280491761 hasConceptScore W4280491761C524204448 @default.
• W4280491761 hasConceptScore W4280491761C71924100 @default.
• W4280491761 hasConceptScore W4280491761C72563966 @default.
• W4280491761 hasConceptScore W4280491761C8891405 @default.
• W4280491761 hasIssue "5" @default.
• W4280491761 hasLocation W42804917611 @default.
• W4280491761 hasLocation W42804917612 @default.

• next